Population-Level Benefits from Providing Effective HIV Prevention Means to Pregnant Women in High Prevalence Settings
Figure 3
Comparison of the impact of interventions with 70% efficacious VMB used consistently by 60% of the non-pregnant women under different scenarios of VMB use by pregnant women: A) Cumulative fraction of infections prevented over 10 years in women (red), men (blue) and total (green) assuming no change in HIV risk during pregnancy (RRHIV/preg = 1); B) Cumulative fraction of infections prevented in women; C) Projected HIV prevalence after 10 years assuming no VMB use and VMB use by non-pregnant women only.
D) Cumulative fraction of infections during pregnancy prevented over 10 years. The scenarios with elevated risk during pregnancy use parameter combinations described in Fig. 2A. The box plots (median, 5th, 25th, 75th, 95th percentiles) reflect the variation in estimates generated by 1,000 different epidemic sets.